25-Mar-2026
Business Wire (Thu, 5-Mar 4:01 PM ET)
CareDx Grants Inducement Equity Awards to 35 New Hires—What Does This Signal for Investors?
Market Chameleon (Mon, 2-Mar 3:54 AM ET)
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 27-Feb 4:01 PM ET)
CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer
Business Wire (Tue, 24-Feb 5:15 PM ET)
CareDx Announces Fourth Quarter and Full Year 2025 Financial Results
Business Wire (Tue, 24-Feb 4:01 PM ET)
CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference
Business Wire (Wed, 18-Feb 8:00 AM ET)
Business Wire (Thu, 12-Feb 7:05 AM ET)
CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Business Wire (Tue, 10-Feb 4:01 PM ET)
Business Wire (Tue, 3-Feb 7:05 AM ET)
Business Wire (Tue, 27-Jan 4:05 PM ET)
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Caredx trades on the NASDAQ stock market under the symbol CDNA.
As of March 25, 2026, CDNA stock price climbed to $18.08 with 671,039 million shares trading.
CDNA has a beta of 0.59, meaning it tends to be less sensitive to market movements. CDNA has a correlation of 0.02 to the broad based SPY ETF.
CDNA has a market cap of $962.34 million. This is considered a Small Cap stock.
Last quarter Caredx reported $108 million in Revenue and $.12 earnings per share. This beat revenue expectation by $6 million and missed earnings estimates by -$.11.
In the last 3 years, CDNA traded as high as $34.84 and as low as $4.80.
The top ETF exchange traded funds that CDNA belongs to (by Net Assets): ARKG, VTI, XBI, IWM, VXF.
CDNA has underperformed the market in the last year with a return of -7.8%, while the SPY ETF gained +15.7%. In the last 3 month period, CDNA fell short of the market, returning -8.4%, while SPY returned -4.6%. However, in the most recent 2 weeks CDNA has outperformed the stock market by returning +6.5%, while SPY returned -2.7%.
CDNA support price is $17.29 and resistance is $18.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CDNA shares will trade within this expected range on the day.